Hydrocortisone Pharmline (Hydrocortisone Sodium Succinate)

Hydrocortisone Pharmline is indicated for several acute medical conditions that require rapid glucocorticoid replacement or anti‑inflammatory action.

• Treatment of adrenal insufficiency, including Addison’s disease, when oral therapy is not feasible.
• Management of acute adrenal crisis to restore cortisol levels promptly.
• Control of severe inflammatory or allergic reactions such as anaphylaxis or asthma exacerbations.
• Support in shock states where cortisol deficiency contributes to hemodynamic instability.
• Adjunct therapy in certain surgical or trauma settings to reduce systemic inflammation.

• Hydrocortisone sodium succinate is a water‑soluble pro‑drug that is rapidly converted to active hydrocortisone after intramuscular or intravenous injection. The active molecule binds intracellular glucocorticoid receptors, translocates to the nucleus, and modulates gene transcription. This results in decreased synthesis of pro‑inflammatory cytokines, inhibition of phospholipase A2, and suppression of immune cell activation, producing anti‑inflammatory and immunosuppressive effects through multiple downstream pathways.

Adverse reactions to Hydrocortisone Pharmline can range from mild and transient to rare but serious events.

Common

• Pain, redness, or swelling at the injection site, usually resolving within a few hours.
• Temporary increase in blood glucose levels, which may require monitoring in patients with diabetes.
• Mild electrolyte changes such as slight reduction in potassium concentration.
• Fluid retention that can cause short‑term weight gain or peripheral edema.

Serious

• Severe hypersensitivity reactions, including rash, bronchospasm, or anaphylactic shock.
• Acute adrenal insufficiency if the drug is stopped abruptly after prolonged use.
• Marked elevation of blood pressure or exacerbation of pre‑existing hypertension.
• Increased susceptibility to bacterial, viral, or fungal infections due to immune suppression.

Before initiating Hydrocortisone Pharmline, clinicians should evaluate several safety considerations to minimize risks.

• Assess for known hypersensitivity to hydrocortisone or any formulation components.
• Use caution in patients with uncontrolled diabetes, as glucocorticoids can raise blood glucose.
• Evaluate cardiovascular status; existing hypertension or heart failure may be worsened.
• Monitor electrolyte balance, particularly potassium and sodium, during therapy.
• Consider the risk of infection; avoid use in active systemic infections when possible.
• Do not discontinue abruptly after prolonged therapy to prevent adrenal crisis.
• Pregnancy and lactation status should be reviewed; safety data are limited.

Hydrocortisone Pharmline may interact with other medications, influencing efficacy or safety.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce glucocorticoid levels.
• Combining with other systemic corticosteroids, which can increase the risk of systemic side effects.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) because of additive gastrointestinal ulcer risk.
• Anticoagulants, as glucocorticoids may enhance anticoagulant effects and increase bleeding risk.
• Vaccines, particularly live attenuated vaccines, due to possible reduced immune response.
• Diuretics, which may exacerbate electrolyte disturbances when used together.